Seroatlas · Human Serome Atlas

SFTPA2

Pulmonary surfactant-associated protein A2

Also known as: COLEC5, SFPA2_HUMAN, SP-A2

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: Q8IWL1
Gene: SFTPA2
Ensembl: ENSG00000185303
Chromosome: 10
Canonical length: 248 aa
Protein class: Disease related genes, Human disease related genes, Predicted secreted proteins
Secretome location: Secreted in other tissues
Quaternary structure: Homotrimer

OverviewNCBI Gene

This gene is one of several genes encoding pulmonary-surfactant associated proteins (SFTPA) located on chromosome 10. Mutations in this gene and a highly similar gene located nearby, which affect the highly conserved carbohydrate recognition domain, are associated with idiopathic pulmonary fibrosis. The current version of the assembly displays only a single centromeric SFTPA gene pair rather than the two gene pairs shown in the previous assembly which were thought to have resulted from a duplication. [provided by RefSeq, Sep 2009]

Canonical amino-acid sequenceUniProt

248 residues, UniProt reviewed canonical sequence.

>Q8IWL1|SFTPA2
     1  MWLCPLALTL ILMAASGAAC EVKDVCVGSP GIPGTPGSHG LPGRDGRDGV KGDPGPPGPM
    61  GPPGETPCPP GNNGLPGAPG VPGERGEKGE AGERGPPGLP AHLDEELQAT LHDFRHQILQ
   121  TRGALSLQGS IMTVGEKVFS SNGQSITFDA IQEACARAGG RIAVPRNPEE NEAIASFVKK
   181  YNTYAYVGLT EGPSPGDFRY SDGTPVNYTN WYRGEPAGRG KEQCVEMYTD GQWNDRNCLY
   241  SRLTICEF

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against SFTPA2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Secreted
Secreted: Yes
Transmembrane segments: 0
Mean surface accessibility (rSASA): 0.47
Highest tissue expression: 10,182 nTPM

Expression across tissuesHPA

Tissue

lung: 10,182 nTPM
prostate: 25 nTPM
adrenal gland: 11 nTPM
stomach: 9.9 nTPM
seminal vesicle: 7.8 nTPM
spleen: 6.3 nTPM

Single-cell type

alveolar cells type 2: 19,330 nCPM
transitional alveolar cells: 3,437 nCPM
alveolar cells type 1: 391 nCPM
respiratory ionocytes: 130 nCPM
submucosal glandular cells: 58 nCPM
respiratory ciliated cells: 56 nCPM

Immune cell

plasmacytoid DC: 0.3 nTPM
basophil: 0 nTPM
classical monocyte: 0 nTPM
eosinophil: 0 nTPM
gdT-cell: 0 nTPM
intermediate monocyte: 0 nTPM

Brain region

cerebellum: 7.8 nTPM
pons: 3.9 nTPM
cerebral cortex: 3.2 nTPM
white matter: 2.5 nTPM
basal ganglia: 2.1 nTPM
hypothalamus: 2.1 nTPM

DiseaseUniProt · ClinVar · IEDB · PubMed

Four sources answering four different questions about SFTPA2.

Disease | AllUniProt

Conditions SFTPA2 is implicated in, by any mechanism.

Interstitial lung disease 2 (ILD2) MIM:178500

Disease | GeneticClinVar

6 pathogenic / likely-pathogenic of 108 ClinVar records.

Conditions with pathogenic or likely-pathogenic variants.

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 1.27
gnomAD pLI: 0.01
gnomAD missense Z: -1.16
DepMap mean gene effect: 0.03
DepMap dependency class: none

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

respiratory gaseous exchange by respiratory system

Molecular functions

carbohydrate binding

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads SFTPA2 as an antibody target. Whether an autoantibody or antibody against SFTPA2 could matter depends on whether native SFTPA2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

SFTPA2 is annotated as secreted, so native SFTPA2 circulates and is directly accessible to antibodies. Secreted and cell-surface proteins are the autoantibody targets most likely to act like drugs, blocking or depleting the native protein.

Annotation status

The present source text does not explicitly label SFTPA2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...